跳至主要内容
临床试验/NCT00960856
NCT00960856已完成1 期

A Four Arm, Single-Dose, Food Effect Evaluation With 105 mg Fenofibric Acid Tablets Administered in a Fasted State and Three Different Fed Conditions, Low-Fat/Low Calorie Meal, Standard Meal, and High-Fat/High Calorie Meal

Mutual Pharmaceutical Company, Inc.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
40
试验地点
1
主要终点
Maximum Plasma Concentration (Cmax)

研究概览

简要总结

The primary objective of this study is to characterize the single-dose pharmacokinetic profile of fenofibric acid (105 mg tablets) and the effect of food of various calorie/fat compositions on the rate and extent of absorption. Additionally, the safety and tolerability of this dose and regimen of fenofibric acid will be evaluated.

详细描述

The primary objective of this study is to determine the single-dose pharmacokinetic profile of fenofibric acid (105 mg tablets) and the effect of food of various calorie/fat compositions on the rate and extent of absorption. Forty healthy, non-smoking, non-obese, non-pregnant adult volunteers between the ages of 18 and 45 years old will receive a single oral dose of fenofibric acid in one of four randomly assigned sequences of meal conditions each separated by a 7 day washout period. On study Days 1, 8, 15 and 22 each subject will receive a single oral dose (1 x 105 mg tablet) of fenofibric acid following an overnight fast of at least 10 hours or with a low-fat meal, standard meal, or high-fat/high-calorie meal according to their randomization sequence. Subjects will fast for at least 4.25 hours after dosing in each of the four dosing conditions. Blood samples will be drawn from all participants before dosing and for 72 hours post-dose at times sufficient to adequately define the pharmacokinetics of fenofibric acid. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Seated blood pressure and heart rate will be measured prior to dosing and at 2 hours post-dose. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drug and/or procedures. All adverse events whether elicited by query, spontaneously reported, or observed by clinic staff will be evaluated by the Investigator and reported in the subject's case report form.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy adults between the ages of 18 and 45
  • Non-smoking
  • Non-pregnant (post-menopausal, surgically sterile, or using effective contraceptive measures)
  • Body mass index (BMI) less than 30
  • Medically healthy on the basis of medical history and physical examination
  • Hemoglobin > or = to 12g/dL
  • Completion of the screening process within 28 days prior to dosing
  • Provision of voluntary written informed consent

排除标准

  • Recent participation (within 28 days) in other research studies
  • Recent significant blood donation or plasma donation
  • Pregnant or lactating
  • Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)
  • Recent (2-year) history or evidence of alcoholism or drug abuse
  • History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  • Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study
  • Drug allergies to fenofibric acid

研究组 & 干预措施

Fenofibric Acid 105 mg - Low-Fat Meal

Experimental

Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.

干预措施: Fenofibric Acid 105 mg Tablet (Drug)

Fenofibric Acid 105 mg - Standard Meal

Experimental

Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a standard breakfast.

干预措施: Fenofibric Acid 105 mg Tablet (Drug)

Fenofibric Acid 105 mg - High-Fat/High-Calorie Meal

Experimental

Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.

干预措施: Fenofibric Acid 105 mg Tablet (Drug)

Fenofibric Acid 105 mg - Fasted State

Experimental

Fenofibric Acid 105 mg tablet administered after an overnight fast of at least 10 hours

干预措施: Fenofibric Acid 105 mg Tablet (Drug)

结局指标

主要结局

Maximum Plasma Concentration (Cmax)

时间窗: serial pharmacokinetic blood samples drawn immediately prior to dosing and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours after dose administration

The maximum or peak concentration that the drug reaches in the plasma.

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

时间窗: serial pharmacokinetic blood samples drawn immediately prior to dosing and then 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours after dose administration

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.

The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)

时间窗: serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after drug administration.

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验